Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

About this update from Jazz Pharmaceuticals Plc

Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S . media and investors only DUBLIN , June 4, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 , in Baltimore . The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia. "People living with narcolepsy and idiopathic hypersomnia, while profoundly affected by symptoms, face challenges in diagnosis and navigating treatment considerations," said Jessa Alexander, Ph.D., neuroscience therapeutic area head, global medical and scientific affairs of Jazz Pharmaceuticals. "The research Jazz is unveiling at SLEEP 2026 is rooted in the day-to-day realities of patients, reflecting our commitment to conduct studies that mirror real-world experiences and treatment paradigms. This comprehensive approach allows our research to inform care decisions and address the full complexity of these conditions, spanning the 24-hour burden of sleep inertia, daytime symptoms and sleep as well as the meaningful implications of reducing long-term sodium intake." Key highlights at SLEEP 2026 include: An oral presentation featuring a post-hoc analysis of the DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) study, examining objective and subjective sleep inertia in participants with narcolepsy (type 1 and type 2) taking Xywav. Two poster presentations reporting post-hoc analyses of the DUET study exploring outcomes for idiopathic hypersomnia participants taking Xywav treatment, with one evaluating objective and patient-reported sleep inertia and the other exploring outcomes of Xywav treatment when stratified by individual ideal sleep duration. A poster presentation showcasing changes in hypersomnolence among participants with narcolepsy taking Xywav dosages >9 grams per night, compared to 9 grams at baseline, in the DUET study. The current recommended dosage of Xywav for adults with narcolepsy is 6-9 grams per night. Six poster presentations featuring comprehensive findings from the real-world, longitudinal, mixed-methods LYRICAL study, examining the treatment experience and dosing patterns of U.S . adults with idiopathic hypersomnia or narcolepsy taking Xywav. Two poster presentations detailing the development of conceptual disease models of the symptoms and impact of narcolepsy type 1 and narcolepsy type 2, respectively, from the patient perspective to better understand the most bothersome symptoms and meaningful impacts. The SLEEP 2026 abstracts are available online at: sleepmeeting.org/abstract-supplements . The full list of Jazz's presentations at SLEEP 2026 is: Presentation Title Authors Presentation Details Improvements in Sleep Inertia With Low-Sodium Oxybate Treatment in Participants With Narcolepsy Type 1 and Type 2 in the DUET Study Nichols DA, Schneider LD, Plante DT, Dai J, Steininger TL, Whalen M, Cairns A, Ruoff CM, Van Dongen HPA Type: Oral and poster Oral Session : O-23 Oral Date/Time: June 17, 2026 , 4:45-5:00 p.m. ET Poster Session: P-35 Poster Date/Time: June 16 , 2026,10:00-11:45 a.m. ET Poster Board Number: 339 Clinical Responders to Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia Ruoff CM, Sangal RB, Nichols DA, Steininger TL, Dai J, Vahabzadeh S, Whalen W, Markt SC, Herpel LB, Foldvary-Schaefer N Type: Late-breaking oral and poster Oral Session : LBA-02 Oral Date/Time: June 16, 2026 , 11:00-11:15 a.m. ET Poster Session: P-41 Poster Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 421 Estimating the Prevalence of Diagnosed Idiopathic Hypersomniain the Pediatric Population: A US Claims Analysis Gavrielov-Yusim N, Markt SC, Nelms J, Bhattacharjee R, Maski K Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 539 Clinically Relevant Symptoms of Narcolepsy and Idiopathic Hypersomnia in Patients Initiating Low-Sodium Oxybate: Electronic Health Record Notes Study Markt SC, Whalen M, Drachenberg C, Beaty S, Alexander JK, CasstevensC, Fee RM, Russell K, Ortiz LE Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 533 Improvements in Nighttime SleepQuality and Daytime Sleepiness Are Associated With Better Quality of Life in Narcolepsy: Findings From LYRICAL Drachenberg C, Farrell M, D'Souza J, Kim E, Hayes C, Zhang D, Lawrence M, Graham CA, Whalen M, Alexander JK, Beaty S, Markt SC, Herpel LB Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 534 Daytime and Nighttime SymptomImprovements Are Associated With Better Quality of Life in Idiopathic Hypersomnia: Findings From LYRICAL Drachenberg C, Farrell M, D'Souza J, Kim E, Hayes C, Zhang D, Lawrence M, Graham CA, Whalen M, Alexander JK, Beaty S, Markt SC, Herpel LB Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 535 Changes in Cardiovascular and Cardiometabolic Biomarkers Following Low-Sodium Oxybate Initiation for Narcolepsy or Idiopathic Hypersomnia Markt SC, Alexander JK, Hughes AG , Sachdev A, Whalen M, Drachenberg C, Beaty S, Dai J, Black J, Somers VK Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 526 Nocturnal Sleep Features as a Candidate Mechanism for Improvements in Daytime Symptoms in Idiopathic Hypersomnia or Narcolepsy Cairns A, Plante DT, Ruoff CM, Schneider LD, Dai J, Nichols DA, Steininger TL, Whalen M, Markt SC, Bogan RK, Dauvilliers Y, Mignot E Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 537 Nocturnal Sleep Features as Candidates for Evaluating Disease Specific Improvements in Idiopathic Hypersomnia or Narcolepsy Cairns A, Plante DT, Ruoff CM, Schneider LD, Dai J, Nichols DA, Steininger TL, Whalen M, Markt SC, Bogan RK, Dauvilliers Y, Mignot E Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 536 Changes in Patient-Reported Symptoms After Switching From High- to Low-Sodium Oxybate in Participants With Narcolepsy in the XYLO Study Somers VK, Dauvilliers Y, Nichols DA, Markt SC, Baranak C, Dai J, Measey TJ, Whalen M, White WB Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 527 Individualized Dosing and Drug Utilization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia: Results from Post-Marketing Data Gavrielov-Yusim N, Nelms J, Dai J, Balmuri P, Saumweber A, Singer D, Skobieranda F, Patodiya V, Markt S Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 529 Individualized Dosing of Low-Sodium Oxybate in Patients with Narcolepsy or Idiopathic Hypersomnia Foldvary-Schaefer N, Meskill GJ, Nichols DA, Steininger TL, Dai J, Measey T, Whalen M, Cairns A, Schneider LD, Bogan RK Type: Late-breaking poster Session: P-41 Date/Time: June 16, 2026, 10:00-11:45 a.m. ET Poster Board Number: 528 Improvements in Sleep Inertia WithLow-Sodium Oxybate Treatment in Participants With IdiopathicHypersomnia in the DUET Study Nichols DA, Schneider LD, Ruoff CM, Dai J, Steininger TL, Whalen M, Cairns A, Plante DT, Van Dongen HPA Type: Poster Session: P-35 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 338 Patient-Reported Improvement in Hypersomnolence Measures in Participants With Narcolepsy Taking >9 Gram Dosage of Low-Sodium Oxybate in the DUET Study Bogan RK, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Dai J, Measey TJ, Whalen M, Cairns A, Schneider LD, Simmons JH Type: Poster Session: P-35 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 331 Effectiveness and Safety of Low-Sodium Oxybate by Patient-Reported Long Sleep Need in DUET Study Participants With Idiopathic Hypersomnia Plante DT, Ruoff CM, Schneider LD, Nichols DA, Steininger TL, Cairns A, Dai J, Whalen M, Dauvilliers Y Type: Poster Session: P-35 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 325 A Conceptual Disease Model of the Symptoms and Impacts of Narcolepsy Type 1 From the Patient Perspective Casstevens C, Foldvary-Schaefer N, Maski K, Plante DT, Farrell M, Graham CA, Mobley C, KimE, Wraight M, Black J, Steinerman JR, Ortiz LE Type: Poster Session: P-34 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 302 A Conceptual Disease Model of the Symptoms and Impacts of Narcolepsy Type 2 From the Patient Perspective Casstevens C, Maski K,Foldvary-Schaefer N, OrtizLE, Farrell M, Graham CA, Mobley C, Kim E, Wraight M, Black J, Steinerman JR, Plante DT Type: Poster Session: P-34 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 303 Effectiveness and Satisfaction With Low-Sodium Oxybate As Described by Adults Living With Narcolepsy: LYRICAL Survey & Interview Findings Drachenberg C, Farrell M, D'Souza J, Kim E, Lawrence M, Graham CA, Whalen M, Alexander JK, Beaty S, Markt SC, HerpelLB Type: Poster Session: P-38 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 359 Effectiveness and Satisfaction WithLow-Sodium Oxybate As Described by Adults Living With Idiopathic Hypersomnia: LYRICAL Survey & Interview Findings Drachenberg C, Farrell M, D'Souza J, Kim E, Lawrence M, Graham CA, Whalen M, Alexander JK, Beaty S, Markt SC, Herpel LB Type: Poster Session: P-38 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 360 Individualized Dosing With Low-Sodium Oxybate in Narcolepsy: Patient Voices From LYRICAL Drachenberg C, Farrell M, D'Souza J, Kim E, Lawrence M, Graham CA, Whalen M, Alexander JK, Beaty S, Markt SC, Herpel LB Type: Poster Session: P-38 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 362 Individualized Dosing With Low-Sodium Oxybate in Idiopathic Hypersomnia: Patient Voices FromLYRICAL Drachenberg C, Farrell M, D'Souza J, Kim E, Lawrence M, Graham CA,Whalen M, Alexander JK, Beaty S, Markt SC, Herpel LB Type: Poster Session: P-38 Date/Time: June 16, 2026 , 10:00-11:45 a.m. ET Poster Board Number: 361 About Xywav ® (calcium, magnesium, potassium, and sodium oxybates) oral solution Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The FDA recognized seven years of Orphan Drug Exclusivity for Xywav for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. The Office of Orphan Product Development (OOPD) at the FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy by means of greater cardiovascular safety compared to Xyrem® (sodium oxybate) oral solution. The decision of the OOPD is based on the FDA findings that Xywav provides a greatly reduced chronic sodium burden compared to Xyrem. Xywav has 131 mg of sodium at the maximum recommended nightly dose whereas other high sodium oxybates have 1640 mg at the equivalent dose. Xywav is comprised of a unique composition of cations resulting in 92% less sodium, or a reduction of approximately 1,000 to 1,500 mg/night at the recommended dose range of 6 g to 9 g/night. Xywav is the only oxybate therapy that does not carry a warning in the label related to use in patients sensitive to high sodium intake. Xywav is also the first and only FDA-approved treatment option for idiopathic hypersomnia in adults. The FDA recognized seven years of Orphan Drug Exclusivity for Xywav for the treatment of idiopathic hypersomnia in adults. Xywav is the only FDA-approved treatment studied across the multiple symptoms of idiopathic hypersomnia, such as EDS, sleep inertia (severe grogginess or confusion when waking up), long sleep duration and cognitive impairment. Xywav can be administered as a twice- or once-nightly regimen for the treatment of idiopathic hypersomnia in adults. The exact mechanism of action of Xywav in the treatment of adults with idiopathic hypersomnia and of cataplexy and EDS in narcolepsy is unknown. It is hypothesized that the therapeutic effects of Xywav are mediated through GABAB actions during sleep at noradrenergic and dopaminergic neurons, as well as thalamocortical neurons.1 The U.S. Drug Enforcement Agency (DEA) has designated Xywav as a Schedule III medicine. The DEA defines Schedule III drugs, substances, or chemicals as drugs with a moderate to low potential for physical and psychological dependence.1,2 Because of the risks of central nervous system (CNS) depression and abuse and misuse, Xywav is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS. Important Safety Information for Xywav WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. Central Nervous System Depression XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses. Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving CNS stimulants. Abuse and Misuse The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death. Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a REMS called the XYWAV and XYREM REMS. Contraindications XYWAV is contraindicated in combination with sedative hypnotics or alcohol and in patients with succinic semialdehyde dehydrogenase deficiency. Warnings and Precautions Central Nervous System Depression The concurrent use of XYWAV with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and death. If use of these CNS depressants in combination with XYWAV is required, dose reduction or discontinuation of one or more CNS depressants (including XYWAV) should be considered. In addition, if short-term use of an opioid (e.g., post- or perioperative) is required, interruption of treatment with XYWAV should be considered. After first initiating treatment and until certain that XYWAV does not affect them adversely (e.g., impair judgment, thinking, or motor skills), caution patients against hazardous activities requiring complete mental alertness or motor coordination such as operating hazardous machinery, including automobiles or airplanes. Also caution patients against these hazardous activities for at least 6 hours after taking XYWAV. Patients should be queried about CNS depression-related events upon initiation of XYWAV therapy and periodically thereafter. Abuse and Misuse XYWAV is a Schedule Ill controlled substance. The active moiety of XYWAV is oxybate, also known as GHB, a Schedule I controlled substance. Abuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death. The rapid onset of sedation, coupled with the amnestic features of GHB particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g., assault victim). Physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely. XYWAV and XYREM REMS Because of the risks of central nervous system depression and abuse and misuse, XYWAV is available only through a restricted distribution program called the XYWAV and XYREM REMS. Notable requirements of the XYWAV and XYREM REMS include the following: Healthcare Providers who prescribe XYWAV are specially certified XYWAV will be dispensed only by the central pharmacy that is specially certified XYWAV will be dispensed and shipped only to patients who are enrolled in the XYWAV and XYREM REMS with documentation of safe use Further information is available at www.XYWAVXYREMREMS.com or 1-866-997-3688. Respiratory Depression and Sleep-Disordered Breathing XYWAV may impair respiratory drive, especially in patients with compromised respiratory function. In overdoses of oxybate and with illicit use of GHB, life-threatening respiratory depression has been reported. Increased apnea and reduced oxygenation may occur with XYWAV administration in adult and pediatric patients. A significant increase in the number of central apneas and clinically significant oxygen desaturation may occur in patients with obstructive sleep apnea treated with XYWAV. Prescribers should be aware that sleep-related breathing disorders tend to be more prevalent in obese patients, in men, in postmenopausal women not on hormone replacement therapy, and among patients with narcolepsy. Depression and Suicidality In Study 1, the randomized-withdrawal clinical trial in adult patients with narcolepsy (n=201), depression and depressed mood were reported in 3% and 4%, respectively, of patients treated with XYWAV. Two patients (1%) discontinued XYWAV because of depression. In most cases, no change in XYWAV treatment was required. In Study 2, the randomized-withdrawal clinical trial in adult patients with idiopathic hypersomnia (n=154), depression and depressed mood were reported in 1% and 3%, respectively, of patients treated with XYWAV. All patients continued XYWAV treatment. Two suicides and two attempted suicides occurred in adult clinical trials with oxybate (same active moiety as XYWAV). One patient experienced suicidal ideation and two patients reported depression in a pediatric clinical trial with oxybate. These events occurred in patients with and without previous histories of depressive disorders. The emergence of depression in patients treated with XYWAV requires careful and immediate evaluation. Monitor patients for the emergence of increased depressive symptoms and/or suicidality while taking XYWAV. Other Behavioral or Psychiatric Adverse Reactions In Study 1, confusion and anxiety occurred in 1% and 5% of patients with narcolepsy treated with XYWAV, respectively. One patient experienced visual hallucinations and confusion after ingesting approximately 9 grams of XYWAV. In Study 2, confusion and anxiety occurred in 3% and 16% of patients with idiopathic hypersomnia, respectively. One patient experienced visual hallucinations, which led to discontinuation of XYWAV. Other neuropsychiatric reactions reported with oxybate (same active moiety as XYWAV) in adult or pediatric clinical trials and in the postmarketing setting include hallucinations, paranoia, psychosis, aggression, agitation, confusion and anxiety. The emergence or increase in the occurrence of behavioral or psychiatric events in patients taking XYWAV should be carefully monitored. Parasomnias Parasomnias can occur in patients taking XYWAV. In Study 1 and Study 2, parasomnias, including sleepwalking, were reported in 6% and 5% of adult patients treated with XYWAV, respectively. In a clinical trial of XYREM (same active moiety as XYWAV) in adult patients with narcolepsy, five instances of sleepwalking with potential injury or significant injury were reported. Parasomnias, including sleepwalking, have been reported in a pediatric clinical trial with sodium oxybate (same active moiety as XYWAV) and in postmarketing experience with sodium oxybate. Episodes of sleepwalking should be fully evaluated and appropriate interventions considered. Most Common Adverse Reactions The most common adverse reactions (occurring in ≥5% of XYWAV-treated patients in adult clinical trials in either narcolepsy or IH) were nausea, headache, dizziness, anxiety, insomnia, decreased appetite, hyperhidrosis, vomiting, diarrhea, dry mouth, parasomnia, somnolence, fatigue, and tremor. In the pediatric clinical trial with XYREM (same active moiety as XYWAV) that included pediatric patients 7 to 17 years of age with narcolepsy, the most common adverse reactions (≥5%) were nausea (20%), enuresis (19%), vomiting (18%), headache (17%), weight decreased (13%), decreased appetite (9%), dizziness (8%), and sleepwalking (6%). The overall adverse reaction profile of XYREM in the pediatric clinical trial was similar to that seen in the adult clinical trial program. The safety profile in pediatric patients with XYWAV is expected to be similar to that of adult patients treated with XYWAV and to that of pediatric patients treated with XYREM. Additional Adverse Reactions Adverse reactions that occurred in 2-

View stock analysis, news, and events for Jazz Pharmaceuticals Plc